Last updated: February 28, 2026
What is NDC 59746-0115?
NDC 59746-0115 is a specific drug listed under the National Drug Code (NDC) directory. Based on available data, this NDC corresponds to Hepatitis C Virus (HCV) treatment. Exact branding, dosage, and formulation details are needed for precise market positioning; these can vary depending on manufacturer and formulation specifics.
Market Overview
Current Market Size and Trends
- The global hepatitis C drug market was valued at approximately $12.4 billion in 2021 (Source: GlobalData).
- The US market accounted for roughly 45% of revenue in 2021, driven by high prevalence rates and expanding treatment coverage.
- The market experienced rapid growth from 2014-2017 with the introduction of direct-acting antivirals (DAAs). Growth has stabilized but remains steady owing to new formulations and expanded indications.
Key Competitors
- Gilead Sciences: Led with Harvoni, Epclusa, and Vosevi.
- AbbVie: Mavyret.
- Bristol-Myers Squibb: Daklinza.
- Merck: Zepatier.
Prescription Trends
- Approximately 200,000 new treatments initiated annually in the US (Source: IQVIA).
- Increased screening efforts and expanded insurance coverage have driven higher prescription volume.
Regulatory and Patent Landscape
- Gilead's flagship products faced patent cliffs due to generic competition, reducing pricing pressure.
- Several key formulations are protected until 2025-2028, though biosimilars and generics impact pricing dynamics.
Price Trends and Projections
Current Pricing
- The average retail price for a full DAA treatment course ranges from $24,000 to $94,000.
- Commercial insurers negotiate discounts reducing net prices; estimates suggest net prices are approximately 50-70% of list prices.
Historical Price Trends
- Prices peaked around 2015, then decreased as competition increased and generics entered the market.
- Gilead's earlier products like Sovaldi originally listed over $84,000 per course; subsequent products experienced significant discounts.
Future Price Projections (2023-2028)
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$20,000 - $50,000 |
Market saturation, increased generic/biosimilar entry, negotiated discounts |
| 2024-2025 |
$15,000 - $45,000 |
Patent expirations, new formulations, biosimilar market penetration |
| 2026-2028 |
$10,000 - $35,000 |
Continued generics, pricing pressure, potential new licensing agreements |
Drivers of Price Decline
- Entry of biosimilars and generics.
- Market saturation in key geographies.
- Pricing negotiations with payers.
- New formulations with improved dosing or reduced treatment duration.
Considerations for Market Entry or Investment
- Pipeline of competitive drugs and biosimilars.
- Patent expiration timelines for existing treatments.
- Regulatory approval prospects for novel formulations.
- Market access strategies, including insurance negotiations and patient assistance programs.
Key Takeaways
- The hepatitis C drug market is mature, with pricing primarily driven by product exclusivity and competition.
- Prices have declined from peak levels due to increased competition and biosimilars.
- For NDC 59746-0115, current treatment costs likely range between $20,000 and $50,000, with downward pressure expected over the next few years.
- Market growth will be influenced by the uptake of generic products, patent expiry dates, and new therapeutic developments.
FAQs
1. When will patent expiration likely impact the price of NDC 59746-0115?
Patent expirations for key hepatitis C treatments typically occur between 2025 and 2028, opening opportunities for generics and biosimilars to enter the market.
2. How do generic versions affect market prices?
Generics reduce prices through increased competition. Net prices can be 50% or less of brand-name prices once generics are available.
3. What factors could accelerate price declines?
Regulatory approvals of biosimilars, increased market penetration, and payer negotiations can accelerate price reductions.
4. Are there new formulations that could influence pricing?
Yes. Advances such as shorter treatment durations or fixed-dose combinations could shift price points, either upward if perceived as more effective or downward if lowering treatment costs.
5. How does treatment volume impact market valuation?
Higher treatment volume sustains revenue streams, but price reductions can offset volume gains. Market growth depends on screening efforts, treatment access, and guideline recommendations.
References
- GlobalData. (2022). Hepatitis C Virus Disease - Market Analysis and Industry Forecasts.
- IQVIA. (2022). The Impact of Biosimilars on Hepatitis C Treatment.
- U.S. Food and Drug Administration. (2022). Approved Drugs: Hepatitis C Virus Infection.
- Centers for Disease Control and Prevention (CDC). (2021). Hepatitis C Surveillance and Prevalence Data.
- Miller, G., & Jones, R. (2021). Pricing Trends in Hepatitis C Therapies. Journal of Hepatology, 74(2), 347-354.
